Dupilumab in Inflammatory Skin Diseases: A Systematic Review

Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the signaling of interleukin (IL)-4 and -13. Several other chronic skin conditions share mechanistic overlaps with AD in their pathophysiology, i.e., are linked to type 2 inflammation. Most recently, dupilumab was ap...

Descripción completa

Detalles Bibliográficos
Autores principales: Olbrich, Henning, Sadik, Christian D., Ludwig, Ralf J., Thaçi, Diamant, Boch, Katharina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136243/
https://www.ncbi.nlm.nih.gov/pubmed/37189381
http://dx.doi.org/10.3390/biom13040634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136243/
https://www.ncbi.nlm.nih.gov/pubmed/37189381
http://dx.doi.org/10.3390/biom13040634

Ejemplares similares